Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + apatinib + 5-fluorouracil + leucovorin + oxaliplatin + docetaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination regimen is a chemo-immunotherapy strategy being investigated for the treatment of gastric and gastroesophageal junction (G/GEJ) cancers. It integrates the PD-1 inhibitor **camrelizumab** and the VEGFR-2 tyrosine kinase inhibitor **apatinib** with the **FLOT** chemotherapy backbone, which consists of **5-fluorouracil**, **leucovorin**, **oxaliplatin**, and **docetaxel**. The regimen is typically employed in the neoadjuvant or perioperative setting to maximize pathological response and improve surgical outcomes in patients with locally advanced disease. By simultaneously targeting immune evasion, angiogenesis, and rapid cell division, the combination aims to overcome resistance mechanisms common in gastric adenocarcinoma. The development of this specific combination is notably associated with the Affiliated Cancer Hospital of Harbin Medical University.
- Other names
- Camrelizumab plus Apatinib plus FLOTCamrelizumab + Apatinib + FLOT
02
Targets
TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)SRC (Proto-oncogene tyrosine-protein kinase Src)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on camrelizumab + apatinib + 5-fluorouracil + leucovorin + oxaliplatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + apatinib + 5-fluorouracil + leucovorin + oxaliplatin + docetaxel.